Literature DB >> 17414961

The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence.

M Asif A Siddiqui1.   

Abstract

(1) Biologics have had a tremendous impact on the management of rheumatoid arthritis.(2) Three new biologics have been approved or filed for approval for the treatment of rheumatoid arthritis in the last 2 years: abatacept, rituximab, and tocilizumab.(3) The utility of the newer biologics against the background of existing, well established biologics (infliximab, etanercept, adalimumab, and anakinra) has not been evaluated systematically.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17414961     DOI： 10.1097/01.bor.0000265447.48722.04

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN： 1040-8711            Impact factor:   5.006


  10 in total

Review 1.  Tocilizumab: a review of its use in the treatment of juvenile idiopathic arthritis.

Authors:  James E Frampton
Journal:  Paediatr Drugs       Date:  2013-12       Impact factor: 3.022

Review 2.  Role of magnetic resonance imaging in the diagnosis and prognosis of rheumatoid arthritis.

Authors:  Lisa G Suter; Liana Fraenkel; R Scott Braithwaite
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-05       Impact factor: 4.794

3.  Botulinum toxin therapy for osteoarticular pain: an evidence-based review.

Authors:  Jasvinder A Singh
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-04-01       Impact factor: 5.346

Review 4.  Green tea polyphenol epigallocatechin 3-gallate in arthritis: progress and promise.

Authors:  Salahuddin Ahmed
Journal:  Arthritis Res Ther       Date:  2010-04-28       Impact factor: 5.156

5.  Alphavbeta3-targeted nanotherapy suppresses inflammatory arthritis in mice.

Authors:  Hui-Fang Zhou; Happy W Chan; Samuel A Wickline; Gregory M Lanza; Christine T N Pham
Journal:  FASEB J       Date:  2009-04-17       Impact factor: 5.191

Review 6.  Tocilizumab: a review of its use in the management of rheumatoid arthritis.

Authors:  Vicki Oldfield; Sohita Dhillon; Greg L Plosker
Journal:  Drugs       Date:  2009       Impact factor: 9.546

7.  Interleukin-1beta and tumor necrosis factor alpha inhibit chondrogenesis by human mesenchymal stem cells through NF-kappaB-dependent pathways.

Authors:  N Wehling; G D Palmer; C Pilapil; F Liu; J W Wells; P E Müller; C H Evans; R M Porter
Journal:  Arthritis Rheum       Date:  2009-03

8.  Sustained Release of Protein Therapeutics from Subcutaneous Thermosensitive Biocompatible and Biodegradable Pentablock Copolymers (PTSgels).

Authors:  Elizabeth Schaefer; Santhi Abbaraju; Mary Walsh; Donna Newman; Jacklyn Salmon; Rasidul Amin; Sidney Weiss; Ulrich Grau; Poonam Velagaleti; Brian Gilger
Journal:  J Drug Deliv       Date:  2016-10-05

9.  Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences.

Authors:  Matthew L Stoll; Alisa C Gotte
Journal:  Biologics       Date:  2008-06

Review 10.  Clinical use and mechanisms of infliximab treatment on inflammatory bowel disease: a recent update.

Authors:  Yuan Guo; Nonghua Lu; Aiping Bai
Journal:  Biomed Res Int       Date:  2013-01-21       Impact factor: 3.411
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.